Astrazeneca has scored a hit with Imfinzi in the Caspian trial, but the results are unlikely to endanger Roche's Tecentriq.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
Adding immunotherapy to targeted drugs could improve responses in some metastatic melanomas. Two pending pivotal trials will show whether the increased toxicity is worth…
The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…
Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.